Reduced Venetoclax Exposure to 7 Days Vs Standard Exposure with Hypomethylating Agents in Newly Diagnosed AML Patients

Scientists retrospectively compared newly diagnosed AML patients treated with azacitidine x seven days plus venetoclax (VEN) x seven days from the first cycle vs patients treated with standard dose hypomethylating agent + VEN.